PRESS RELEASE published on 01/19/2026 at 07:30, 4 months 2 days ago Inside Information / Other news releases FDA accepts Advicenne's Marketing Authorization Application for Sibnayal® for dRTA treatment in the US, with a PDUFA decision target date of September 3rd, 2026 FDA Advicenne Sibnayal DRTA PDUFA
PRESS RELEASE published on 01/19/2026 at 07:30, 4 months 2 days ago Informations privilégiées / Autres communiqués Advicenne annonce l'acceptation de Sibnayal pour examen par la FDA aux Etats-Unis pour le traitement de l’ATRd. Date PDUFA fixée au 3 septembre 2026 FDA Advicenne ATRd Sibnayal PDUFA
BRIEF published on 01/12/2026 at 07:35, 4 months 9 days ago Renewal of the marketing authorization for Sibnayal® in the European Union Kidney Disease EMA Advicenna AMM Sibnayal®
BRIEF published on 01/12/2026 at 07:35, 4 months 9 days ago Renouvellement de l'AMM de Sibnayal® dans l'Union Européenne Advicenne Maladies Rénales EMA AMM Sibnayal®
PRESS RELEASE published on 01/12/2026 at 07:30, 4 months 9 days ago Informations privilégiées / Autres communiqués Advicenne annonce le succès du renouvellement de l’AMM de Sibnayal® dans l’Union Européenne. L'EMA a validé l'autorisation de mise sur le marché, renforçant le développement commercial de Sibnayal® Renouvellement Union Européenne Advicenne AMM Sibnayal
BRIEF published on 11/04/2025 at 11:35, 6 months 17 days ago Advicenne soumet Sibnayal® à la FDA américaine FDA Advicenne Sibnayal® Acidose Tubulaire Rénale Dépôt D'enregistrement
BRIEF published on 11/04/2025 at 11:35, 6 months 17 days ago Advicenne submits Sibnayal® to the US FDA FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
PRESS RELEASE published on 11/04/2025 at 11:30, 6 months 17 days ago Informations privilégiées / Autres communiqués Advicenne dépose le dossier d'enregistrement de Sibnayal® auprès de la FDA américaine pour le traitement de l'ATRd. Webconférence le 5 novembre 2025. Informations sur ADV7103 et le développement clinique FDA Advicenne Webconférence ATRd Sibnayal
PRESS RELEASE published on 11/04/2025 at 11:30, 6 months 17 days ago Inside Information / Other news releases Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
BRIEF published on 09/19/2025 at 18:05, 8 months 2 days ago Advicenne: Half-year results in 2025 and outlook Financial Results Outlook Turnover United States Sibnayal®
Published on 05/21/2026 at 23:00, 3 hours 33 minutes ago Silver Wolf Adopts Semi-Annual Financial Reporting
Published on 05/21/2026 at 23:00, 3 hours 33 minutes ago Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
Published on 05/21/2026 at 23:00, 3 hours 33 minutes ago Revival Gold Announces Adoption of Shareholder Rights Plan and Corporate Update
Published on 05/21/2026 at 22:15, 4 hours 18 minutes ago Linear Announces Acquisition, Share Consolidation and Private Placement
Published on 05/21/2026 at 21:45, 4 hours 48 minutes ago Rendeavour becomes the African Continental Free Trade Area's inaugural implementation partner for African industrialisation and trade infrastructure
Published on 05/21/2026 at 20:10, 6 hours 23 minutes ago Ernst Russ AG Divests MV 'EF Emira' and Raises Full-Year 2026 Guidance
Published on 05/21/2026 at 20:05, 6 hours 28 minutes ago EQS-Adhoc: Ernst Russ AG: Upward revision of the guidance for the financial year 2026
Published on 05/21/2026 at 20:00, 6 hours 33 minutes ago VINFAST INTRODUCES THE NEW-GENERATION VF 8, FEATURING COMPREHENSIVE ENHANCEMENTS
Published on 05/21/2026 at 18:26, 8 hours 7 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/21/2026 at 17:45, 8 hours 48 minutes ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 05/21/2026 at 17:45, 8 hours 48 minutes ago CEGEDIM: DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 05/21/2026 at 16:35, 9 hours 58 minutes ago 260521 BENETEAU Déclaration du nombre d'actions et de droits de vote au 30-04-2026
